Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$61.93 USD
-3.08 (-4.74%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $62.10 +0.17 (0.27%) 6:50 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Viking Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 362 | 155 | 202 | 248 | 276 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 12 | 8 | 8 | 8 |
Total Current Assets | 367 | 167 | 211 | 256 | 284 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 368 | 169 | 211 | 257 | 284 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 9 | 1 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 13 | 7 | 8 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 19 | 22 | 9 | 12 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 23 | 9 | 12 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 734 | 445 | 426 | 413 | 406 |
Retained Earnings | -378 | -292 | -223 | -168 | -129 |
Other Equity | 0 | -1 | -1 | 0 | 0 |
Treasury Stock | 7 | 7 | 0 | 0 | 0 |
Total Shareholder's Equity | 348 | 145 | 202 | 244 | 277 |
Total Liabilities & Shareholder's Equity | 368 | 169 | 211 | 257 | 284 |
Total Common Equity | 348 | 145 | 202 | 244 | 277 |
Shares Outstanding | 100.00 | 76.60 | 78.20 | 72.90 | 72.20 |
Book Value Per Share | 3.48 | 1.90 | 2.58 | 3.35 | 3.84 |
Fiscal Year End for Viking Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 942 | 963 | 362 | 376 | 393 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 5 | 5 | 6 |
Total Current Assets | 946 | 966 | 367 | 381 | 399 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 947 | 968 | 368 | 383 | 401 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 5 | 8 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 27 | 11 | 7 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 25 | 33 | 19 | 13 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 34 | 20 | 14 | 15 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,351 | 1,341 | 734 | 729 | 725 |
Retained Earnings | -428 | -405 | -378 | -353 | -331 |
Other Equity | -2 | -2 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 7 | 7 | 7 |
Total Shareholder's Equity | 921 | 934 | 348 | 368 | 386 |
Total Liabilities & Shareholder's Equity | 947 | 968 | 368 | 383 | 401 |
Total Common Equity | 921 | 934 | 348 | 368 | 386 |
Shares Outstanding | 110.80 | 110.20 | 100.00 | 100.00 | 100.00 |
Book Value Per Share | 8.31 | 8.47 | 3.48 | 3.68 | 3.86 |